There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Pfizer Inc.’s stock rose 2.8% early Thursday, after the drug company said it has taken a step forward in developing a once-daily pill for obesity ... stage trial of a twice-daily formulation ...

Pfizer said it will continue to develop the once-daily version of its weight loss pill, danuglipron ... giant in December discontinued a twice-daily version of danuglipron after patients had ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... it had decided to drop the twice-daily version, after seeing ...